

# Terri S Armstrong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3551381/publications.pdf>

Version: 2024-02-01

198  
papers

9,243  
citations

81743

39  
h-index

43802

91  
g-index

205  
all docs

205  
docs citations

205  
times ranked

10771  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma. <i>New England Journal of Medicine</i> , 2014, 370, 699-708.	13.9	2,279
2	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. <i>Cancer Cell</i> , 2015, 27, 728-743.	7.7	933
3	Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4085-4091.	0.8	820
4	IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. <i>Acta Neuropathologica</i> , 2015, 129, 585-596.	3.9	272
5	Symptoms Experience: A Concept Analysis. <i>Oncology Nursing Forum</i> , 2003, 30, 601-606.	0.5	197
6	A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 5799-5807.	3.2	166
7	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 2468-2477.	0.8	160
8	A prognostic gene expression signature in infratentorial ependymoma. <i>Acta Neuropathologica</i> , 2012, 123, 727-738.	3.9	148
9	Biology and management of ependymomas. <i>Neuro-Oncology</i> , 2016, 18, 902-913.	0.6	134
10	Net Clinical Benefit Analysis of Radiation Therapy Oncology Group 0525: A Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 4076-4084.	0.8	110
11	Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. <i>Journal of Clinical Oncology</i> , 2017, 35, 361-369.	0.8	109
12	The symptom burden of primary brain tumors: evidence for a core set of tumor- and treatment-related symptoms. <i>Neuro-Oncology</i> , 2016, 18, 252-260.	0.6	105
13	Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. <i>Neuro-Oncology</i> , 2015, 17, 440-447.	0.6	102
14	Chemotherapy-Induced Peripheral Neuropathy. <i>Oncology Nursing Forum</i> , 2005, 32, 305-311.	0.5	101
15	Polymorphisms of <i>LIG4</i> , <i>BTBD2</i> , <i>HMGA2</i> , and <i>RTEL1</i> Genes Involved in the Double-Strand Break Repair Pathway Predict Glioblastoma Survival. <i>Journal of Clinical Oncology</i> , 2010, 28, 2467-2474.	0.8	101
16	Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy: Table 1. <i>Neuro-Oncology</i> , 2016, 18, 779-789.	0.6	101
17	Symptom Clusters in Oncology Patients and Implications for Symptom Research in People with Primary Brain Tumors. <i>Journal of Nursing Scholarship</i> , 2004, 36, 197-206.	1.1	97
18	Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience. <i>Neuro-Oncology</i> , 2010, 12, 862-870.	0.6	94

#	ARTICLE	IF	CITATIONS
19	Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. <i>Neuro-Oncology</i> , 2017, 19, 12-21.	0.6	94
20	Antiepileptic drugs for preventing seizures in people with brain tumors. <i>The Cochrane Library</i> , 2010, CD004424.	1.5	89
21	Heterogeneity within the PF-EPN-B ependymoma subgroup. <i>Acta Neuropathologica</i> , 2018, 136, 227-237.	3.9	86
22	Risk factors for fatigue severity in primary brain tumor patients. <i>Cancer</i> , 2010, 116, 2707-2715.	2.0	77
23	Pregnancy and glial brain tumors. <i>Neuro-Oncology</i> , 2014, 16, 1289-1294.	0.6	76
24	The lomustine crisis: awareness and impact of the 1500% price hike. <i>Neuro-Oncology</i> , 2019, 21, 1-3.	0.6	76
25	Predictors of Survival among Pediatric and Adult Ependymoma Cases: A Study Using Surveillance, Epidemiology, and End Results Data from 1973 to 2007. <i>Neuroepidemiology</i> , 2012, 39, 116-124.	1.1	73
26	Risk analysis of severe myelotoxicity with temozolomide: The effects of clinical and genetic factors. <i>Neuro-Oncology</i> , 2009, 11, 825-832.	0.6	70
27	Venous thromboembolism (VTE) and glioblastoma. <i>Journal of Neuro-Oncology</i> , 2015, 124, 87-94.	1.4	68
28	Content Validity of Self-Report Measurement Instruments: An Illustration From the Development of the Brain Tumor Module of the M.D. Anderson Symptom Inventory. <i>Oncology Nursing Forum</i> , 2005, 32, 669-676.	0.5	66
29	Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus. <i>Neuro-Oncology</i> , 2019, 21, 837-853.	0.6	66
30	Practical strategies for management of fatigue and sleep disorders in people with brain tumors. <i>Neuro-Oncology</i> , 2012, 14, iv65-iv72.	0.6	65
31	Incidence, Risk Factors, and Impact of Severe Neutropenia After Hyperthermic Intraperitoneal Mitomycin C. <i>Annals of Surgical Oncology</i> , 2009, 16, 2181-2187.	0.7	64
32	Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. <i>Journal of Neuro-Oncology</i> , 2015, 125, 401-410.	1.4	59
33	Management of treatment-associated toxicities of anti-angiogenic therapy in patients with brain tumors. <i>Neuro-Oncology</i> , 2012, 14, 1203-1214.	0.6	55
34	Histological Predictors of Outcome in Ependymoma are Dependent on Anatomic Site Within the Central Nervous System. <i>Brain Pathology</i> , 2013, 23, 584-594.	2.1	53
35	Sleep-wake disturbance in patients with brain tumors. <i>Neuro-Oncology</i> , 2016, 19, now119.	0.6	51
36	A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2021, 23, 1337-1347.	0.6	50

#	ARTICLE	IF	CITATIONS
37	Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. <i>Lancet Oncology</i> , The, 2012, 13, e196-e204.	5.1	49
38	Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. <i>Neuro-Oncology</i> , 2021, 23, 1360-1370.	0.6	46
39	High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma. <i>Acta Neuropathologica Communications</i> , 2020, 8, 101.	2.4	45
40	Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report. <i>Lancet Oncology</i> , The, 2020, 21, e97-e103.	5.1	42
41	Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. <i>Neuro-Oncology</i> , 2018, 20, 897-906.	0.6	41
42	Yoga Program for High-Grade Glioma Patients Undergoing Radiotherapy and Their Family Caregivers. <i>Integrative Cancer Therapies</i> , 2018, 17, 332-336.	0.8	40
43	Outcomes After Surgery and Radiotherapy for Spinal Myxopapillary Ependymoma. <i>Neurosurgery</i> , 2014, 75, 205-214.	0.6	39
44	Neuroleptic strategies for terminal agitation in patients with cancer and delirium at an acute palliative care unit: a single-centre, double-blind, parallel-group, randomised trial. <i>Lancet Oncology</i> , The, 2020, 21, 989-998.	5.1	39
45	Clinical Utility of the MDASI-BT in Patients with Brain Metastases. <i>Journal of Pain and Symptom Management</i> , 2009, 37, 331-340.	0.6	38
46	Complementary and Alternative Medicine Use and Quality of Life in Patients with Primary Brain Tumors. <i>Journal of Pain and Symptom Management</i> , 2006, 32, 148-154.	0.6	36
47	Reliability and validity of the M. D. Anderson Symptom Inventoryâ€“Spine Tumor Module. <i>Journal of Neurosurgery: Spine</i> , 2010, 12, 421-430.	0.9	36
48	Personal health records as portal to the electronic medical record. <i>Journal of Neuro-Oncology</i> , 2014, 117, 1-6.	1.4	36
49	Barriers to accrual and enrollment in brain tumor trials. <i>Neuro-Oncology</i> , 2019, 21, 1100-1117.	0.6	36
50	The impact of symptom interference using the MD Anderson Symptom Inventoryâ€“Brain Tumor Module (MDASIâ€“BT) on prediction of recurrence in primary brain tumor patients. <i>Cancer</i> , 2011, 117, 3222-3228.	2.0	35
51	Uncertainty, mood states, and symptom distress in patients with primary brain tumors. <i>Cancer</i> , 2013, 119, 2796-2806.	2.0	35
52	Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. <i>Neuro-Oncology</i> , 2023, 25, 339-350.	0.6	35
53	Clinical course of adult patients with ependymoma. <i>Cancer</i> , 2011, 117, 5133-5141.	2.0	34
54	Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. <i>Acta Neuropathologica</i> , 2021, 142, 827-839.	3.9	33

#	ARTICLE	IF	CITATIONS
55	Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative. <i>Lancet Oncology</i> , The, 2018, 19, e173-e180.	5.1	32
56	Interventions for the management of fatigue in adults with a primary brain tumour. <i>The Cochrane Library</i> , 2016, 2016, CD011376.	1.5	31
57	Envisioning the future in symptom science. <i>Nursing Outlook</i> , 2014, 62, 346-351.	1.5	30
58	Genetic Modulation of Neurocognitive Function in Glioma Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3340-3346.	3.2	29
59	Pilot randomized, controlled trial of a dyadic yoga program for glioma patients undergoing radiotherapy and their family caregivers. <i>Neuro-Oncology Practice</i> , 2019, 6, 311-320.	1.0	29
60	A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. <i>Neuro-Oncology</i> , 2021, 23, 468-477.	0.6	28
61	Congruence of primary brain tumor patient and caregiver symptom report. <i>Cancer</i> , 2012, 118, 5026-5037.	2.0	27
62	A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2020, 22, 1505-1515.	0.6	27
63	Predictors of survival among older adults with ependymoma. <i>Journal of Neuro-Oncology</i> , 2012, 107, 183-189.	1.4	26
64	Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report. <i>Neuro-Oncology</i> , 2016, 18, ii1-ii12.	0.6	26
65	Management of Steroid-Induced Hyperglycemia in Hospitalized Patients With Cancer: A Review. <i>Oncology Nursing Forum</i> , 2014, 41, E355-E365.	0.5	25
66	Radiation chronotherapy—clinical impact of treatment time-of-day: a systematic review. <i>Journal of Neuro-Oncology</i> , 2019, 145, 415-427.	1.4	25
67	Supratentorial gross-totally resected non-anaplastic ependymoma: population based patterns of care and outcomes analysis. <i>Journal of Neuro-Oncology</i> , 2013, 115, 513-520.	1.4	24
68	Imaging techniques in neuro-oncology. <i>Seminars in Oncology Nursing</i> , 2004, 20, 231-239.	0.7	22
69	The relationship between corticosteroids and symptoms in patients with primary brain tumors: utility of the Dexamethasone Symptom Questionnaire—Chronic. <i>Neuro-Oncology</i> , 2015, 17, 1114-1120.	0.6	22
70	Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD). <i>Neuro-Oncology</i> , 2016, 18, ii26-ii36.	0.6	22
71	Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases. <i>Future Oncology</i> , 2020, 16, 899-909.	1.1	22
72	Use of complementary and alternative medical therapy by patients with primary brain tumors. <i>Current Neurology and Neuroscience Reports</i> , 2008, 8, 264-268.	2.0	21

#	ARTICLE	IF	CITATIONS
73	Patient Reported Endpoints for Measuring Clinical Benefit in (High Grade Glioma) Primary Brain Tumor Patients. <i>Current Treatment Options in Oncology</i> , 2014, 15, 519-528.	1.3	21
74	Clinical presentation and outcomes for adult ependymoma patients. <i>Cancer</i> , 2017, 123, 494-501.	2.0	21
75	Clinical and demographic predictors of concussion resolution in adolescents: A retrospective study. <i>Applied Neuropsychology: Child</i> , 2019, 8, 50-60.	0.7	21
76	Validation of the Mishelâ€™s uncertainty in illness scale-brain tumor form (MUIS-BT). <i>Journal of Neuro-Oncology</i> , 2012, 110, 293-300.	1.4	20
77	Health-related quality of life and other clinical outcome assessments in brain tumor patients: challenges in the design, conduct and interpretation of clinical trials. <i>Neuro-Oncology Practice</i> , 2015, 2, 2-5.	1.0	20
78	Hope and mood changes throughout the primary brain tumor illness trajectory. <i>Neuro-Oncology</i> , 2016, 18, 119-125.	0.6	20
79	Ependymomas arising outside of the central nervous system: A case series and literature review. <i>Journal of Clinical Neuroscience</i> , 2018, 47, 202-207.	0.8	19
80	Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT. <i>Journal of Neuro-Oncology</i> , 2019, 144, 53-63.	1.4	19
81	Net clinical benefit: Functional endpoints in brain tumor clinical trials. <i>Current Oncology Reports</i> , 2007, 9, 60-65.	1.8	18
82	Glioblastoma. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 105, 485-506.	1.0	18
83	Wound healing complications in brain tumor patients on Bevacizumab. <i>Journal of Neuro-Oncology</i> , 2015, 124, 501-506.	1.4	18
84	INNV-33. BARRIERS TO ACCRUAL AND ENROLLMENT IN BRAIN TUMOR TRIALS. <i>Neuro-Oncology</i> , 2019, 21, vi137-vi137.	0.6	18
85	Neurocognitive function (NCF) outcomes in patients with glioblastoma (GBM) enrolled in RTOG 0825.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2004-2004.	0.8	18
86	C11orf95â€™RELA fusion present in a primary supratentorial ependymoma and recurrent sarcoma. <i>Brain Tumor Pathology</i> , 2015, 32, 105-111.	1.1	17
87	A case of soft tissue metastasis from glioblastoma and review of the literature. <i>Journal of Neuro-Oncology</i> , 2011, 103, 167-172.	1.4	16
88	Brain Tumor Symptoms as Antecedents to Uncertainty: An Integrative Review. <i>Journal of Nursing Scholarship</i> , 2012, 44, 145-155.	1.1	16
89	Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas. <i>Clinical Cancer Research</i> , 2021, 27, 3298-3306.	3.2	15
90	NCOG-01. PRESERVATION OF NEUROCOGNITIVE FUNCTION (NCF) WITH HIPPOCAMPAL AVOIDANCE DURING WHOLE-BRAIN RADIOTHERAPY (WBRT) FOR BRAIN METASTASES: PRELIMINARY RESULTS OF PHASE III TRIAL NRG ONCOLOGY CC001. <i>Neuro-Oncology</i> , 2018, 20, vi172-vi172.	0.6	14

#	ARTICLE	IF	CITATIONS
91	Nursing Guide to Management of Major Symptoms in Patients with Malignant Glioma. <i>Seminars in Oncology Nursing</i> , 2018, 34, 513-527.	0.7	14
92	Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas. <i>Cancers</i> , 2021, 13, 6092.	1.7	14
93	Central nervous system toxicity from cancer treatment. <i>Current Oncology Reports</i> , 2004, 6, 11-19.	1.8	13
94	The impact and incidence of altered body image in patients with head and neck tumors: a systematic review. <i>Neuro-Oncology Practice</i> , 2018, 5, 204-213.	1.0	13
95	High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13. <i>Acta Neuropathologica</i> , 2022, 143, 403-414.	3.9	13
96	Seize the Moment to Learn About Epilepsy in People With Cancer. <i>Clinical Journal of Oncology Nursing</i> , 2003, 7, 163-169.	0.3	12
97	Living with a central nervous system (CNS) tumor: findings on long-term survivorship from the NIH Natural History Study. <i>Neuro-Oncology Practice</i> , 2021, 8, 460-474.	1.0	12
98	Primary brain tumors and posterior reversible encephalopathy syndrome. <i>Neuro-Oncology Practice</i> , 2014, 1, 184-190.	1.0	11
99	Personal health records, symptoms, uncertainty, and mood in brain tumor patients. <i>Neuro-Oncology Practice</i> , 2014, 1, 64-70.	1.0	11
100	Symptoms and socio-economic impact of ependymoma on adult patients: results of the Adult Ependymoma Outcomes Project 2. <i>Journal of Neuro-Oncology</i> , 2015, 121, 341-348.	1.4	11
101	Head's Up on the Treatment of Malignant Glioma Patients. <i>Oncology Nursing Forum</i> , 2009, 36, E232-E240.	0.5	10
102	Impact of recall period on primary brain tumor patient's self-report of symptoms. <i>Neuro-Oncology Practice</i> , 2014, 1, 55-63.	1.0	10
103	Significant predictors of patients' uncertainty in primary brain tumors. <i>Journal of Neuro-Oncology</i> , 2015, 122, 507-515.	1.4	10
104	Survivorship care planning in neuro-oncology. <i>Neuro-Oncology Practice</i> , 2018, 5, 3-9.	1.0	10
105	Use of virtual reality for symptom management in solid-tumor patients with implications for primary brain tumor research: a systematic review. <i>Neuro-Oncology Practice</i> , 2020, 7, 477-489.	1.0	10
106	Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825). <i>Neuro-Oncology</i> , 2021, 23, 1125-1138.	0.6	10
107	Measuring Clinical Benefit: Use of Patient-Reported Outcomes (PRO) in Primary Brain Tumor Clinical Trials. <i>Current Oncology Reports</i> , 2013, 15, 27-32.	1.8	9
108	Provider-reported challenges and barriers to referring patients to neuro-oncology clinical trials: a report from the Society for Neuro-Oncology member survey. <i>Neuro-Oncology Practice</i> , 2020, 7, 38-51.	1.0	9

#	ARTICLE	IF	CITATIONS
109	Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative. <i>Neuro-Oncology Practice</i> , 2021, 8, 417-425.	1.0	9
110	Association of Circadian Clock Gene Expression with Glioma Tumor Microenvironment and Patient Survival. <i>Cancers</i> , 2021, 13, 2756.	1.7	9
111	Increased Intracranial Pressure. <i>Clinical Journal of Oncology Nursing</i> , 2008, 12, 37-41.	0.3	8
112	Seizure risk in brain tumor patients with conversion to generic levetiracetam. <i>Journal of Neuro-Oncology</i> , 2010, 98, 137-141.	1.4	8
113	Relationship between symptom burden and health status: analysis of the MDASI-BT and EQ-5D. <i>Neuro-Oncology Practice</i> , 2018, 5, 56-63.	1.0	8
114	SNO 2020 diversity survey: defining demographics, racial biases, career success metrics and a path forward for the field of neuro-oncology. <i>Neuro-Oncology</i> , 2021, 23, 1845-1858.	0.6	8
115	Neurocognition and Health-Related Quality of Life Among Patients with Brain Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 269-282.	0.9	8
116	Quality improvement in neurology. <i>Neurology</i> , 2018, 90, 652-658.	1.5	7
117	Association of genetic variants with fatigue in patients with malignant glioma. <i>Neuro-Oncology Practice</i> , 2018, 5, 122-128.	1.0	7
118	Impacts of Surgery on Symptom Burden and Quality of Life in Pituitary Tumor Patients in the Subacute Post-operative Period. <i>Frontiers in Oncology</i> , 2019, 9, 299.	1.3	7
119	Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes. <i>Neurosurgery</i> , 2019, 84, 66-76.	0.6	7
120	Effects of Cognitive Reserve on Cognition in Individuals With Central Nervous System Disease. <i>Cognitive and Behavioral Neurology</i> , 2021, 34, 245-258.	0.5	7
121	Development of "Core Outcome Sets"™ for Meningioma in Clinical Studies (The COSMIC Project): protocol for two systematic literature reviews, eDelphi surveys and online consensus meetings. <i>BMJ Open</i> , 2022, 12, e057384.	0.8	7
122	Recurrent ACVR1 mutations in posterior fossa ependymoma. <i>Acta Neuropathologica</i> , 2022, 144, 373-376.	3.9	7
123	See brain cancer as more than just the sum of biology. <i>Nature</i> , 2018, 561, S45-S45.	13.7	6
124	The prevalence of altered body image in patients with primary brain tumors: an understudied population. <i>Journal of Neuro-Oncology</i> , 2020, 147, 397-404.	1.4	6
125	Burnout and career satisfaction in neuro-oncology: a survey of the Society for Neuro-Oncology and the European Association of Neuro-Oncology memberships. <i>Neuro-Oncology</i> , 2020, 22, 838-850.	0.6	6
126	Impact of age on the circadian visual system and the sleep-wake cycle in mus musculus. <i>Npj Aging and Mechanisms of Disease</i> , 2021, 7, 10.	4.5	6



#	ARTICLE	IF	CITATIONS
127	Validation study of the Japanese version of MD Anderson Symptom Inventory for Brain Tumor module. Japanese Journal of Clinical Oncology, 2020, 50, 787-793.	0.6	6
128	The treatment of neoplastic meningitis. Expert Opinion on Pharmacotherapy, 2004, 5, 1929-1935.	0.9	5
129	Quality improvement in neurology: Neuro-Oncology Quality Measurement Set. Neuro-Oncology, 2018, 20, 531-537.	0.6	5
130	The association between BMI and BSAâ€œtemozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525. Neuro-Oncology Practice, 2019, 6, 473-478.	1.0	5
131	Progress in rare central nervous system tumors. Current Opinion in Neurology, 2019, 32, 895-906.	1.8	5
132	Challenges of imaging interpretation to predict oligodendroglioma grade: a report from the Neuro-Oncology Branch. CNS Oncology, 2022, 11, CNS83.	1.2	5
133	Opportunities and challenges for the development of â€œcore outcome setsâ€œ in neuro-oncology. Neuro-Oncology, 2022, 24, 1048-1055.	0.6	5
134	Chemotherapy of astrocytomas: an overview. Seminars in Oncology Nursing, 1998, 14, 18-25.	0.7	4
135	Seizures in People With Cancer. Clinical Journal of Oncology Nursing, 2007, 11, 33-37.	0.3	4
136	Caring for an adult with a malignant primary brain tumor. Nursing, 2011, 41, 28-33.	0.2	4
137	Facing the Future of Brain Tumor Clinical Research. Clinical Cancer Research, 2014, 20, 5591-5600.	3.2	4
138	NCI-CONNECT: Comprehensive Oncology Network Evaluating Rare CNS Tumorsâ€œHistone Mutated Midline Glioma Workshop Proceedingsâ€œ. Neuro-Oncology Advances, 2020, 2, vdaa007.	0.4	4
139	Proposed Additions to the NCCN Guidelines for Adult Medulloblastoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1579-1584.	2.3	4
140	Exploring the prevalence and burden of sleep disturbance in primary brain tumor patients. Neuro-Oncology Practice, 2022, 9, 526-535.	1.0	4
141	Survivorship in Neuro-Oncology. Neuro-Oncology, 2018, 20, vii4-vii5.	0.6	3
142	RDNA-04. CIRCADIAN RHYTHMS AND RADIATION CHRONOTHERAPY IN GLIOBLASTOMA CELL LINES AND CENTRAL NERVOUS SYSTEM CELL CONTROLS. Neuro-Oncology, 2019, 21, vi207-vi207.	0.6	3
143	Variations in attitudes towards stereotactic biopsy of adult diffuse midline glioma patients: a survey of members of the AANS/CNS Tumor Section. Journal of Neuro-Oncology, 2020, 149, 161-170.	1.4	3
144	The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment. Neuro-Oncology Advances, 2021, 3, vdab035.	0.4	3

#	ARTICLE	IF	CITATIONS
145	Report of Canonical <i>BCR</i> - <i>ABL1</i> Fusion in Glioblastoma. <i>JCO Precision Oncology</i> , 2021, 5, 1348-1353.	1.5	3
146	Psychometric validity and reliability of the Danish version of the MD Anderson Symptom Inventory Brain Tumor Module. <i>Neuro-Oncology Practice</i> , 2021, 8, 137-147.	1.0	3
147	Assessing mobility in primary brain tumor patients: A descriptive feasibility study using two established mobility tests. <i>Neuro-Oncology Practice</i> , 0, , .	1.0	3
148	A systematic review of pharmacologic treatment efficacy for depression in older patients with cancer. <i>Brain, Behavior, &amp; Immunity - Health</i> , 2022, 21, 100449.	1.3	3
149	The Montreal Cognitive Assessment (MoCA) in neuro-oncology: A pilot study of feasibility and utility in telehealth and in-person clinical assessments. <i>Neuro-Oncology Practice</i> , 2022, 9, 429-440.	1.0	3
150	Glial Tumors-New Approaches in Chemotherapy. <i>Journal of Neuroscience Nursing</i> , 2002, 34, 326-330.	0.7	2
151	Introduction. <i>Seminars in Oncology Nursing</i> , 2004, 20, 221-223.	0.7	2
152	Patient Profiling for Treatment Toxicity: Potential Use of Clinical and Genomic Factors. <i>Current Oncology Reports</i> , 2011, 13, 37-41.	1.8	2
153	Reply to M.C. Chamberlain. <i>Journal of Clinical Oncology</i> , 2014, 32, 1634-1635.	0.8	2
154	Exploring the Cancer Experiences of Young Adults in the Context of Stem Cell Transplantation. <i>Cancer Nursing</i> , 2015, 38, 260-269.	0.7	2
155	PATH-28. THE NATURAL HISTORY OF BRAF V600E-MUTATED GLIOBLASTOMAS IN ADULTS. <i>Neuro-Oncology</i> , 2018, 20, vi164-vi164.	0.6	2
156	RARE-24. OBJECTIVE RESPONSE AND CLINICAL BENEFIT IN RECURRENT EPENDYMOMA IN ADULTS: FINAL REPORT OF CERN 08-02: A PHASE II STUDY OF DOSE-DENSE TEMOZOLOMIDE AND LAPATINIB. <i>Neuro-Oncology</i> , 2018, 20, vi241-vi241.	0.6	2
157	Clinical trial challenges, design considerations, and outcome measures in rare CNS tumors. <i>Neuro-Oncology</i> , 2021, 23, S30-S38.	0.6	2
158	Identifying symptom recurrences in primary brain tumor patients using the MDASI-BT and qualitative interviews. <i>Journal of Patient-Reported Outcomes</i> , 2019, 3, 58.	0.9	2
159	Venous thromboembolism (VTE) and glioblastoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2033-2033.	0.8	2
160	Histological analysis of sleep and circadian brain circuitry in cranial radiation-induced hypersomnolence (C-RIH) mouse model. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
161	INNV-41. MY STORI – A SYMPTOM TRACKING AND REPORTING INSTRUMENT MOBILE APPLICATION FOR CENTRAL NERVOUS SYSTEM CANCER PATIENTS. <i>Neuro-Oncology</i> , 2018, 20, vi146-vi146.	0.6	1
162	ACTR-13. A BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB VERSUS BEVACIZUMAB PLUS VORINOSTAT IN ADULTS WITH RECURRENT GLIOBLASTOMA FINAL RESULTS. <i>Neuro-Oncology</i> , 2018, 20, vi13-vi13.	0.6	1

#	ARTICLE	IF	CITATIONS
163	QOLP-06. BODY IMAGE DISTURBANCE IN PATIENTS WITH PRIMARY BRAIN TUMORS. <i>Neuro-Oncology</i> , 2018, 20, vi215-vi215.	0.6	1
164	PATH-52. UTILIZING NEXT GENERATION SEQUENCING REPORTS IN CLINICAL DECISION MAKING: REPORT FROM THE NATIONAL INSTITUTES OF HEALTH (NIH) NEURO-ONCOLOGY BRANCH (NOB) NATURAL HISTORY STUDY (NHS) PRIMARY BRAIN TUMOR PANEL (PBTP). <i>Neuro-Oncology</i> , 2018, 20, vi170-vi170.	0.6	1
165	Describing Symptom Burden and Functional Status at the Diagnosis of Leptomeningeal Metastasis. <i>Oncology Nursing Forum</i> , 2018, 45, 372-379.	0.5	1
166	QOLP-30. CLINICAL PREDICTIVE MODEL FOR THE DEVELOPMENT OF VENOUS THROMBOEMBOLISM IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, vi204-vi204.	0.6	1
167	QOLP-36. THE IMPORTANCE OF SLEEP DISTURBANCE IN PRIMARY BRAIN TUMOR (PBT) PATIENTS: CLINICAL CHARACTERISTICS & CO-OCCURRENCE WITH TUMOR-RELATED & PSYCHOLOGICAL SYMPTOMS. <i>Neuro-Oncology</i> , 2019, 21, vi205-vi206.	0.6	1
168	Letter to the Editor Re: Mohile et al. <i>Neuro-Oncology</i> , 2020, 22, 1048-1049.	0.6	1
169	Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 601452.	1.3	1
170	Phase II Trial of Proton Therapy vs. Photon IMRT for GBM: Secondary Analysis Comparison of Progression Free Survival between RANO vs. Clinical Assessment. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab073.	0.4	1
171	Accrual and access to neuro-oncology trials in the United States. <i>Neuro-Oncology Advances</i> , 2022, 4, vdac048.	0.4	1
172	Differences in Circulating Extracellular Vesicle and Soluble Cytokines in Older Versus Younger Breast Cancer Patients With Distinct Symptom Profiles. <i>Frontiers in Genetics</i> , 2022, 13, 869044.	1.1	1
173	Cuidar de un adulto con un tumor cerebral primario maligno. <i>Nursing (Ed Espa�ola)</i> , 2011, 29, 8-13.	0.0	0
174	Response to Lai et al., "Development of a Symptom Index for Patients with Primary Brain Tumors" Value in Health, 2014, 17, 752-753.	0.1	0
175	Psycho-oncology. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 305-313.	1.0	0
176	QOLP-16. CAPTURING THE PRIMARY BRAIN TUMOR (PBT) PATIENTS' EXPERIENCE OF BODY IMAGE DISSATISFACTION: REPORT FROM THE NEURO-ONCOLOGY BRANCH-NATURAL HISTORY STUDY (NOB-NHS). <i>Neuro-Oncology</i> , 2018, 20, vi217-vi218.	0.6	0
177	RARE-21. A DESCRIPTIVE REPORT OF PATIENTS WITH RARE CENTRAL NERVOUS SYSTEM (CNS) CANCERS ON AN NCI-CONNECT CANCER MOONSHOT IMMUNE CHECKPOINT INHIBITOR TRIAL. <i>Neuro-Oncology</i> , 2018, 20, vi240-vi240.	0.6	0
178	INNV-43. NUCLEIC ACID ADEQUACY FROM ARCHIVED FORMALIN-FIXED PARAFFIN EMBEDDED (FFPE) TUMOR TISSUE FOR NEXT-GENERATION SEQUENCING (NGS) IN NATIONAL CANCER INSTITUTE (NCI)- NATURAL HISTORY STUDY (NHS) OF PRIMARY CNS TUMOR. <i>Neuro-Oncology</i> , 2018, 20, vi146-vi146.	0.6	0
179	HOUT-12. CHARACTERIZATION OF SYMPTOM BURDEN IN MINORITY PATIENTS WITH CNS TUMORS: A REPORT FROM THE NEURO-ONCOLOGY BRANCH (NOB) NATURAL HISTORY STUDY (NHS). <i>Neuro-Oncology</i> , 2018, 20, vi115-vi115.	0.6	0
180	INNV-38. THE NEURO-ONCOLOGY BRANCH TRANSLATIONAL RESEARCH IMMERSION PROGRAM: RESULTS FROM TWO YEARS OF DEVELOPMENT AND PARTICIPANT FEEDBACK. <i>Neuro-Oncology</i> , 2018, 20, vi145-vi146.	0.6	0

#	ARTICLE	IF	CITATIONS
181	EXTH-61. PARTNERSHIP FOR DEFINING THE IMPACT OF 12 SELECT RARE CNS TUMORS: A REPORT FROM CBTRUS AND THE NCI-CONNECT. <i>Neuro-Oncology</i> , 2018, 20, vi98-vi98.	0.6	0
182	HOUT-03. SCREENING FOR MOOD DISTURBANCE IN LONG-TERM CENTRAL NERVOUS SYSTEM (CNS) TUMOR SURVIVORS USING PATIENT REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS): A NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS) REPORT. <i>Neuro-Oncology</i> , 2018, 20, vi113-vi113.	0.6	0
183	IMMU-68. SINGLE-CELL PROTEOMIC ANALYSIS OF IMMUNE CELL RESPONSE TO CHECKPOINT BLOCKADE USING 30-PARAMETER FLOW CYTOMETRY. <i>Neuro-Oncology</i> , 2018, 20, vi137-vi137.	0.6	0
184	QOLP-09. ASSOCIATION BETWEEN BODY IMAGE INVESTMENT AND ALTERATION IN PATIENTS WITH PRIMARY BRAIN TUMORS. <i>Neuro-Oncology</i> , 2018, 20, vi216-vi216.	0.6	0
185	RARE-26. MUTATIONS IN MAPK PATHWAY GENES ARE CHARACTERISTIC AND CONFIRMATORY OF MULTINODULAR AND VACUOLATING NEURONAL TUMOR OF THE CEREBRUM. <i>Neuro-Oncology</i> , 2018, 20, vi241-vi241.	0.6	0
186	INNV-33. IMPLEMENTATION OF ELECTRONIC DATA CAPTURE FOR USE IN NATURAL HISTORY STUDIES: UTILITY OF CENTER FOR CANCER RESEARCHS (CCR) LABMATRIX AND SCRIBE SYSTEMS FOR THE NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS). <i>Neuro-Oncology</i> , 2018, 20, vi145-vi145.	0.6	0
187	QOLP-26. PATIENT REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS) SCREENING FOR ANXIETY & DEPRESSION IN CENTRAL NERVOUS SYSTEM(CNS) CANCER: LARGE COHORT REPORT FROM THE NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS).. <i>Neuro-Oncology</i> , 2018, 20, vi220-vi220.	0.6	0
188	RDNA-13. VALIDATION OF BEHAVIORAL ANALYSIS ACROSS AGE IN A MOUSE MODEL FOR FUTURE INVESTIGATION OF RADIATION-INDUCED HYPERSOMNOLENCE (RIH) IN PRIMARY BRAIN TUMOR (PBT) PATIENTS. <i>Neuro-Oncology</i> , 2018, 20, vi224-vi224.	0.6	0
189	QOLP-28. THE USE OF VIRTUAL REALITY FOR SYMPTOM MANAGEMENT: APPLICATION IN NEURO-ONCOLOGY. <i>Neuro-Oncology</i> , 2019, 21, vi203-vi204.	0.6	0
190	NIMG-03. PROSPECTIVE PHASE II RANDOMIZED TRIAL COMPARING PROTON THERAPY VS. PHOTON IMRT FOR GBM: SECONDARY ANALYSIS COMPARISON OF PROGRESSION FREE SURVIVAL BETWEEN RANO VS. CLINICAL AND RADIOLOGICAL ASSESSMENT. <i>Neuro-Oncology</i> , 2019, 21, vi161-vi162.	0.6	0
191	QOLP-31. ASSESSING THE IMPACT OF GLIOBLASTOMA ON WORK PRODUCTIVITY IN PATIENTS AND THEIR CAREGIVERS. <i>Neuro-Oncology</i> , 2019, 21, vi204-vi204.	0.6	0
192	HOUT-01. ALOPECIA SYMPTOM IMPACT SCALE (ASIS): MEASURING THE SYMPTOMS OF ALOPECIA AND THEIR IMPACT IN PATIENTS WITH PRIMARY BRAIN TUMORS. <i>Neuro-Oncology</i> , 2019, 21, vi111-vi112.	0.6	0
193	HOUT-22. EVALUATING CLINICAL IMPACT UTILIZING THE RANO-PRO COLLABORATIVE'S STANDARDIZED PRIORITY CONSTRUCTS. <i>Neuro-Oncology</i> , 2019, 21, vi116-vi117.	0.6	0
194	NIMG-32. CHALLENGES OF IMAGING INTERPRETATION TO PREDICT OLIGODENDROGLIOMA GRADE. <i>Neuro-Oncology</i> , 2019, 21, vi168-vi168.	0.6	0
195	“The value of experience is not in seeing much, but in seeing wisely” Sa. <i>Neuro-Oncology Practice</i> , 2019, 6, 413-414.	1.0	0
196	Glioma patient-reported outcome assessment in clinical care “ Authors' reply. <i>Lancet Oncology</i> , The, 2020, 21, e231.	5.1	0
197	QOLP-14. PRELIMINARY EXAMINATION OF CONFIRMED GLIOMA RISK FACTORS AMONG EPENDYMOMA PATIENTS IN THE NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS) AND RISK AND OUTCOMES STUDY (ROS). <i>Neuro-Oncology</i> , 2018, 20, vi217-vi217.	0.6	0
198	Associations of meaning of illness with psychosocial, clinical, and immunological characteristics in patients with Leptomeningeal metastasis. <i>Comprehensive Psychoneuroendocrinology</i> , 2021, 8, 100099.	0.7	0